CytomX
IPOUnited States · $50.0M raised
- Employees
- 51–200
- Business Model
- B2B
- Total Funding
- $50.0M
- Last Round
- $20.0M Series CJan 2013
- Rounds
- 2
About
Clinical-stage oncology biopharmaceutical company developing PROBODY therapeutics designed to activate selectively in the tumor microenvironment.
Summary
CytomX is a Biotech company based in United States. It has raised $50.0M in total across 2 rounds, most recently a $20.0M Series C round in Jan 2013. Investors include Third Rock Ventures, Pfizer Ventures and Canaan Partners.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2015
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company